Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L DeMets

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
The American Journal of Clinical Nutrition|October 13, 2017
Surrogate disease markers as substitutes for chronic disease outcomes in studies of diet and chronic disease relationsElizabeth A Yetley, David L DeMets, William R Harlan
JAMA|December 21, 2017
Guidelines for Statistical Analysis PlansDavid L DeMets, Thomas D Cook, Kevin A Buhr
Journal of the National Cancer Institute|November 21, 2002
Re: The influence of menstrual cycle phase on surgical treatment of primary breast cancer: have we made any progress over the past 13 years?Richard R Love, D Craig Allred, David L DeMets
JAMA|December 14, 2016
Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring CommitteesRoger J Lewis, Karim A Calis, David L DeMets
Journal of Biopharmaceutical Statistics|June 23, 2004
Conditional bias of point estimates following a group sequential testXiaoyin Frank Fan, David L DeMets, K K Gordon Lan
The American Journal of Medicine|February 5, 2020
Aspirin in Primary Prevention: Needs Individual Clinical JudgmentsAlexander Gitin, Marc A Pfeffer, David L DeMets, et al.
Science and Engineering Ethics|November 25, 2016
Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and AccountabilityDavid L DeMets, Thomas R Fleming, Gail Geller, et al.
Statistics in Medicine|July 27, 2010
Some drop-the-loser designs for monitoring multiple dosesY H Joshua Chen, David L Demets, K K Gordon Lan
Controlled Clinical Trials|February 1, 2003
Monitoring mortality at interim analyses while testing a composite endpoint at the final analysisY H Joshua Chen, David L DeMets, K K Gordon Lan
Statistics in Medicine|April 2, 2004
Increasing the sample size when the unblinded interim result is promisingY H Joshua Chen, David L DeMets, K K Gordon Lan
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
The American Journal of Clinical Nutrition|October 13, 2017
Surrogate disease markers as substitutes for chronic disease outcomes in studies of diet and chronic disease relationsElizabeth A Yetley, David L DeMets, William R Harlan
JAMA|December 21, 2017
Guidelines for Statistical Analysis PlansDavid L DeMets, Thomas D Cook, Kevin A Buhr
Journal of the National Cancer Institute|November 21, 2002
Re: The influence of menstrual cycle phase on surgical treatment of primary breast cancer: have we made any progress over the past 13 years?Richard R Love, D Craig Allred, David L DeMets
JAMA|December 14, 2016
Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring CommitteesRoger J Lewis, Karim A Calis, David L DeMets
Journal of Biopharmaceutical Statistics|June 23, 2004
Conditional bias of point estimates following a group sequential testXiaoyin Frank Fan, David L DeMets, K K Gordon Lan
The American Journal of Medicine|February 5, 2020
Aspirin in Primary Prevention: Needs Individual Clinical JudgmentsAlexander Gitin, Marc A Pfeffer, David L DeMets, et al.
Science and Engineering Ethics|November 25, 2016
Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and AccountabilityDavid L DeMets, Thomas R Fleming, Gail Geller, et al.
Statistics in Medicine|July 27, 2010
Some drop-the-loser designs for monitoring multiple dosesY H Joshua Chen, David L Demets, K K Gordon Lan
Controlled Clinical Trials|February 1, 2003
Monitoring mortality at interim analyses while testing a composite endpoint at the final analysisY H Joshua Chen, David L DeMets, K K Gordon Lan
Statistics in Medicine|April 2, 2004
Increasing the sample size when the unblinded interim result is promisingY H Joshua Chen, David L DeMets, K K Gordon Lan
Pageof 10